Ratings Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
14.6 ^USD	-3.76%		+10.19%	+55.15%

May. 06	Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024
May. 06	Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ENANTA PHARMACEUTICALS, INC.	+55.15%	309M	C+
MODERNA, INC.	+22.81%	46.81B	B-
LONZA GROUP AG	+46.68%	41.29B	A
IQVIA HOLDINGS INC.	-1.88%	41.37B	B
CELLTRION, INC.	-6.20%	28.87B	C
ICON PUBLIC LIMITED COMPANY	+11.33%	26.06B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B	B
BIO-TECHNE CORPORATION	-1.43%	11.96B	B+
MEDPACE HOLDINGS, INC.	+30.73%	12.39B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	12.08B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes